Umeclidinium for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 8, Issue 6, 2014, Pages 665-671

  Segreti, Andrea ^a   Calzetta, Luigino ^b   Rogliani, Paola ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

bronchodilators; COPD; ElliptaTM inhaler; LAMA; umeclidinium bromide

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; UMECLIDINIUM; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INHALER; META ANALYSIS (TOPIC); RHINOPHARYNGITIS; SINUS TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; XEROSTOMIA; DRUG EFFECTS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TREATMENT OUTCOME;

EID: 84910658406     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.962519     Document Type: Article

References (35)

1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64: 450-504
2. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014; 35(1):191-201
3. National Institute for Health and Clinical Excellence. CG101 Chronic Obstructive Pulmonary Disease (update): full guideline 23 June 2010. Available from: www.nice.org [Last accessed 30 April 2014]
4. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
5. Global initiative for chronic Obstructive Lung Disease.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2014. Available from: www. goldcopd.org/ [Last accessed 30 April 2014]
6. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol 2012;48:247-57
7. Cazzola M, Page C, Matera MG. Long-Acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26:307-17
8. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15:961-77
9. Anonymous. GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD. Available from: www.gsk.com/media/press-releases/2014/gskreceives- eu-marketing-Authorisation-for-incruse-umeclidiniu.html [Last accessed 12 May 2014]
10. Anonymous. GSK receives approval for IncruseTM Ellipta- (umeclidinium) in the US for the treatment of COPD. Available from: -www.gsk.com/media/press-releases/2014/gsk-receives-Approval-for-incruseellipta umeclidinium-in-the.html [Last accessed 15 May 2014]
11. Lainé DI, McCleland B, Thomas S, et al. Discovery of novel 1-Azoniabicyclo[2.2.2] octane muscarinic acetylcholine receptor antagonists. J Med Chem 2009;52: 2493-505
12. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-Acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013;345:260-70
13. Cahn A, Tal-Singer R, Pouliquen IJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Investig 2013;33:477-88
14. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol 2013;701:40-8
15. Goyal N, Beerahee M, Kalberg C, et al. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 2014;53(7):637-48
16. Lainé DI, Luttmann MA, Foley JJ, et al. The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing [abstract]. Eur Respir J 2011; 38(Suppl 5):613s
17. Cahn A, Mehta R, Preece A, et al. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial. Clin Drug Investig 2013;33:653-64
18. Mehta R, Kelleher D, Preece A, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis 2013;8:159-67
19. Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013;13:72
20. Church A, Beerahee M, Brooks J, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med 2014;14:2
21. Donohue JF, Anzueto A, Brooks J, et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012;106:970-9
22. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-Acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013;185:393-9
23. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014;43:72-81
24. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/ 25 mcg in COPD: a randomized, controlled study. Chest 2014. [Epub ahead of print]
25. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538-46
26. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. J Stat Software 2012;49:1-15
27. Turner JR, Durham TA. Metamethodology: conducting and reporting meta-Analyses. J Clin Hypertens (Greenwich) 2014;16:91-3
28. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Software 2010;36:1-48
29. FDA Advisory Committee Briefing Document. ANOROTM ELLIPTATM (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease. Available from: www.fda.gov/downloads/ AdvisoryCommittees/Committees MeetingMaterials/Drugs/Pulmonary- AllergyDrugsAdvisoryCommittee/ UCM367414.pdf [Last accessed 15 May 2014]
30. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
31. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8
32. 24-week Trial Comparing GSK573719/ GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease. Available from: http:// clinicaltrials.gov/show/NCT01316913
33. ClinicalTrials.gov. 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease. Available from: https://clinicaltrials.gov/ct2/ show/NCT01316913?term=umeclidinium +tiotropium&rank=1 [Last accessed 15 May 2014]
34. Gordon J. GlaxoSmithKline. Upgrading to Neutral, upside from upcoming catalysts balances out earnings risk. Available from: https://markets.jpmorgan.com/research/ email/eevpt8pp/GPS-1190044-0.pdf [Last accessed 12 May 2014]
35. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/ vilanterol. Drug Des Devel Ther 2013;7: 1201-8